Search

Displaying results 3411 - 3420 of 4300 in total
  1. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  2. Drug

    (S)-Warfarin

    go.drugbank.com/drugs/DB14055
    Investigational

    Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.

  3. Drug

    Autologous Non-Hematopoietic Peripheral Blood Stem Cells

    go.drugbank.com/drugs/DB15867
    Investigational

    Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center.

  4. Drug

    Jaktinib

    go.drugbank.com/drugs/DB17545
    Investigational

    Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.

  5. Drug

    Asundexian

    go.drugbank.com/drugs/DB19088
    Investigational

    Asundexian is under investigation in clinical trial NCT05686070 (A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk

  6. Drug

    EP-2104R

    go.drugbank.com/drugs/DB05675
    Experimental

    It is being developed by EPIX Pharmaceuticals, Inc.

  7. Drug

    Edodekin alfa

    go.drugbank.com/drugs/DB15631
    Investigational

    investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by

  8. Drug

    Talnetant

    go.drugbank.com/drugs/DB06429
    Investigational

    Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential

  9. Drug

    BLX-883

    go.drugbank.com/drugs/DB05904
    Investigational

    BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C.

  10. Drug

    NSI-566

    go.drugbank.com/drugs/DB17954
    Investigational

    Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).[L47097]